Spire Wealth Management’s Travere Therapeutics TVTX Stock Holding History

Spire Wealth Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.1K	Buy	+600	New	+$26.6K	﹤0.01%	1282

Other funds holding TVTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Spire Wealth Management's TVTX Position: Q2 2026 in Review

Spire Wealth Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 600 shares worth $34.1K. The stake represents ﹤0.01% of the portfolio and ranks #1282 among its holdings.

17 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Spire Wealth Management held 600 shares of Travere Therapeutics worth $34.1K as of Q2 2026.
Travere Therapeutics was a new Spire Wealth Management position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #1282 holding.
17 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.